CClinicalTrials.gg
Status unknownNCT05309889Updated May 31, 2022

A Prospective Observational Study of Sepsis

An observational study in Sepsis, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-31.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
174
Ages
18 Years and older
Sex
All
01

Study summary

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and is associated with high morbidity and mortality. Sepsis3 gives sepsis a broad definition, reflecting the heterogeneity of the disease. So we need a precise treatment with a stratification of patient prognosis in order to reduce mortality in patients with sepsis.

02

Conditions studied

  • Sepsis

Browse trials for

03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.

This study's planned enrollment of 174 is close to the median of 160 across 931 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 466 studies on the registry; 271 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who were hospitalized in the ICU of Sun Yat-sen Memorial Hospital of Sun Yat-sen University and met the Sepsis 3 diagnostic criteria.

Inclusion criteria

  • Patients who met the Sepsis3 diagnostic criteria.

Exclusion criteria

Exclusion Criteria:

  • Absence of laboratory test items (blood routine examination, coagulation function, liver function, biochemistry, urine routine examination, urine renal function, urine protein, etc.) >20%.
  • Admission in ICU less than 48 hours.
  • Patient with psychiatric disorders.
  • Under 18 years of age.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
174 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes

Groups and cohorts

  • high exposure level

    Patients have a high level of exposure factors

    Other: no intervention

  • low exposure level

    Patients have a low level of exposure factors

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. mortality rate

    all-cause deaths that occurred in 28 days

    Time frame: 28 days after diagnosis of sepsis

07

Study locations

1 of 1 sites recruiting
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Guangzhou, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05309889
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Responsible party
Sponsor
First posted
Apr 4, 2022
Start date
May 12, 2022
Primary completion
May 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
May 31, 2022

Study contacts

Yuewei Li
Contact
liyw7@mail2.sysu.edu.cn
020-81332587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion